FindTrial
Sign In

Debio 1143

DRUG3 trials

Sponsors

Debiopharm International SA

Conditions

Carcinoma, Non-Small-Cell LungNeoplasmsSolid TumorSquamous Cell Carcinoma of the Head and Neck

Phase 1

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
CompletedNCT03270176
Debiopharm International SACarcinoma, Non-Small-Cell Lung, Neoplasms
Start: 2017-10-10End: 2022-03-22Updated: 2022-06-01
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
CompletedNCT04122625
Debiopharm International SASolid Tumor
Start: 2019-04-26End: 2022-04-06Updated: 2023-06-12

Unknown Phase

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
CompletedNCT02022098
Debiopharm International SASquamous Cell Carcinoma of the Head and Neck
Start: 2013-10-31End: 2022-04-28Updated: 2022-06-23

Related Papers

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study
Therapeutic Advances in Medical Oncology2025-01-01
Phase 2 study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation.
Journal of Clinical Oncology2024-06-011 citations
Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells
Cancer Cell International2024-05-243 citations
Abstract CT140: A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a proton pump inhibitor in healthy volunteers
Cancer Research2024-04-05
Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Clinical Pharmacology & Therapeutics2023-10-014 citations
Long-term Results from a Clinical Study of Xevinapant Plus Chemoradiotherapy in People With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Plain Language Summary
Future Oncology2023-07-135 citations
Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Journal of Clinical Oncology2023-06-01
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
2023-01-0933 citations
589 Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti–PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial
Regular and Young Investigator Award Abstracts2022-11-013 citations
Abstract 5424: Selection of RP3D of xevinapant in combination with CRT in patients with LA SCCHN
Cancer Research2022-06-151 citations
Abstract 3443: The IAP antagonist xevinapant, in combination with high-dose cisplatin chemoradiotherapy, induces NF-kB and apoptotic pathway biomarkers in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
Cancer Research2022-06-15
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
2020-08-0390 citations
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.
Journal of Clinical Oncology2019-05-206 citations
Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).
Journal of Clinical Oncology2019-05-201 citations
Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).
Journal of Clinical Oncology2019-03-013 citations
A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Journal of Clinical Oncology2014-05-201 citations